Károly Tóth

ORCID: 0000-0001-6624-9683
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Virus-based gene therapy research
  • Fluoride Effects and Removal
  • Viral Infectious Diseases and Gene Expression in Insects
  • Dental Health and Care Utilization
  • CAR-T cell therapy research
  • Viral gastroenteritis research and epidemiology
  • Hungarian Social, Economic and Educational Studies
  • RNA Interference and Gene Delivery
  • Cancer Research and Treatments
  • Immunotherapy and Immune Responses
  • Cytomegalovirus and herpesvirus research
  • Peripheral Artery Disease Management
  • T-cell and B-cell Immunology
  • Vascular Procedures and Complications
  • Dental Erosion and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Drug Transport and Resistance Mechanisms
  • Cancer therapeutics and mechanisms
  • Herpesvirus Infections and Treatments
  • Oral microbiology and periodontitis research
  • Carcinogens and Genotoxicity Assessment
  • Immune Cell Function and Interaction
  • Salivary Gland Disorders and Functions
  • Cancer Immunotherapy and Biomarkers
  • Computational Drug Discovery Methods

Saint Louis University
2015-2024

UCLouvain Saint-Louis Brussels
2023-2024

University of Szeged
1965-2024

Bács-Kiskun Megyei Kórház
2010-2023

Roswell Park Comprehensive Cancer Center
2005-2015

Centre for Cancer Biology
2014

Nanjing Medical University
2013

Shandong First Medical University
2013

Semmelweis University
2009-2012

Catholic University of Daegu
2009

ABSTRACT We have constructed two novel adenovirus (Ad) replication-competent vectors, named KD1 and KD3, that may use in anticancer therapy. The vectors key features. First, they markedly overexpress the Ad death protein (ADP), an nuclear membrane glycoprotein required at late stages of infection for efficient cell lysis release from cells. Overexpression ADP was achieved by deleting E3 region reinserting adp gene. Because is overexpressed, KD3 are expected to spread more rapidly effectively...

10.1128/jvi.74.13.6147-6155.2000 article EN Journal of Virology 2000-07-01

Prostate cancer remains the second leading cause of deaths among American men. Early diagnosis increases survival rate in patients; however, treatments for advanced disease are limited to hormone ablation techniques and palliative care. Thus, new methods treatment necessary inhibiting prostate progression. Here, we have shown that miRNA-29b (miR-29b) expression was lower cells (PC3 LNCaP) as compared with immortalized epithelial cells. Between these two cell lines, metastatic PC3 displayed...

10.1158/1535-7163.mct-12-0100 article EN Molecular Cancer Therapeutics 2012-03-09

The anatomical patterns and frequency of occurrence congenital coronary anomalies (CCA) in a Central European cohort has not yet been studied. angiographic data 7,694 consecutive patients undergoing arteriography at the Albert Szent-Györgyi Medical University, Szeged, Hungary, from 1984 to 1994 were analyzed. CCA found 103 (1.34% incidence). Ninety-eight them (95.2%) had origin distribution, five (4.8%) artery fistulae. incidence was highest for separate left descending circumflex sinus...

10.1002/(sici)1097-0304(199711)42:3<270::aid-ccd8>3.0.co;2-9 article EN Catheterization and Cardiovascular Diagnosis 1997-11-01

Abstract Oncolytic adenoviruses represent an innovative approach to cancer therapy. These vectors are typically evaluated in immunodeficient mice with human xenograft tumors. However, addition being immunodeficient, this model is limited because normal and cancerous mouse tissues poorly permissive for adenovirus replication. This prompted us search a that more accurately reflects the use of oncolytic patients. To end, we developed novel Syrian hamster both immunocompetent...

10.1158/0008-5472.can-05-3497 article EN Cancer Research 2006-02-01

Adenoviruses (Ads) cause a wide array of end-organ and disseminated diseases in severely immunosuppressed patients. For example, ≈20% pediatric allogeneic hematopoietic stem cell transplant recipients develop Ad infection, the disease proves fatal as many 50–80% these infections are serious problem for solid-organ AIDS patients well. Unfortunately, there no antiviral drugs approved specifically to treat infections. A suitable animal model that is permissive replication would help discovery...

10.1073/pnas.0800200105 article EN Proceedings of the National Academy of Sciences 2008-05-20

Limited data exist on radial access in carotid artery stenting. This multicentre prospective randomised study was performed to compare the outcome and complication rates of transradial transfemoral stenting.The clinical angiographic 260 consecutive patients with high risk for endarterectomy, treated between 2010 2012 by stenting cerebral protection, were evaluated. Patients (n=130) or groups several parameters Primary combined endpoint: major adverse cardiac events, rate access-site...

10.4244/eijv10i3a64 article EN EuroIntervention 2014-07-01

The continuous spread of SARS-CoV-2 calls for more direct-acting antiviral agents to combat the highly infectious variants. main protease (Mpro) is an promising target anti-SARS-CoV-2 drug design. Here, we report discovery potent non-covalent non-peptide Mpro inhibitors featuring a 1,2,4-trisubstituted piperazine scaffold. We systematically modified hit MCULE-5948770040 by structure-based rational design combined with multi-site binding and privileged structure assembly strategies. optimized...

10.1021/acs.jmedchem.2c01146 article EN Journal of Medicinal Chemistry 2022-09-15

We recently described an immunocompetent Syrian hamster model for oncolytic adenoviruses (Ads) that permits virus replication in tumor cells as well some normal tissues. This allows exploration of interactions between the virus, tumor, organs, and host immune system could not be examined immunodeficient or nonpermissive animal models previously used Ad field. Here we asked whether response to enhances limits antitumor efficacy. first determined cyclophosphamide (CP) is a potent...

10.1038/mt.2008.162 article EN cc-by-nc-nd Molecular Therapy 2008-08-07

Abstract Understanding the role of different subtypes tumor-infiltrating lymphocytes (TIL) in immunosuppressive tumor microenvironment is essential for improving cancer treatment. Enriched γδ1 T-cell populations TILs suppress responses and dendritic cell maturation breast cancer, where their presence correlated negatively with clinical outcomes. However, mechanism(s) that explain increase this class regulatory T cells (γδ Treg) patients have yet to be elucidated. In study, we show IP-10...

10.1158/0008-5472.can-13-0348 article EN Cancer Research 2013-08-20

Clear cell renal carcinoma (ccRCC) accounts for more than 80% of the cases carcinoma. In ccRCC deactivation Von-Hippel-Lindau (VHL) gene contributes to constitutive expression hypoxia inducible factors 1 and 2 alpha (HIF-α), transcriptional regulators several genes involved in tumor angiogenesis, glycolysis drug resistance. We have demonstrated inhibition HIF-1α by Se-Methylselenocysteine (MSC) via stabilization prolyl hydroxylases 3 (PHDs) a significant therapeutic synergy when combined...

10.1186/1471-2407-12-293 article EN cc-by BMC Cancer 2012-07-17

Identification and development of drugs that can effectively modulate the therapeutic efficacy toxicity chemotherapy remain an unmet challenge. We evaluated effects Se-methylselenocysteine (MSC) on antitumour activity cyclophosphamide, cisplatin, oxaliplatin, irinotecan in animal models. Cyclophosphamide, oxaliplatin were administered by a single i.v. injection weekly × 4 schedules. For combination, MSC was daily via oral route for 7 days mice 14 rats before concurrent with drug...

10.1038/bjc.2014.85 article EN cc-by-nc-sa British Journal of Cancer 2014-03-11

ABSTRACT We have previously described two replication-competent adenovirus vectors, named KD1 and KD3, for potential use in cancer gene therapy. KD3 small deletions the E1A that restrict efficient replication of these vectors to human cell lines. These also increased capacity lyse cells spread from because they overexpress death protein, an protein required lysis release cell. now describe a new vector, KD1-SPB, which is vector with E4 promoter replaced by surfactant B (SPB). SPB activity...

10.1128/jvi.75.7.3314-3324.2001 article EN Journal of Virology 2001-04-01

ABSTRACT Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis through two receptors, TRAIL-R1 (also known as death receptor 4) and TRAIL-R2 5), that are members of the TNF superfamily domain-containing receptors. We show human adenovirus type 5 encodes three proteins, named RID (previously E3-10.4K/14.5K), E3-14.7K, E1B-19K, independently inhibit TRAIL-induced infected cells. This conclusion was derived from studies using wild-type adenovirus,...

10.1128/jvi.75.19.8875-8887.2001 article EN Journal of Virology 2001-10-01

Abstract Purpose: Our previously reported therapeutic synergy between naturally occurring seleno-amino acid methylselenocysteine (MSC) and anticancer drugs could not be shown in vitro. Studies were carried out to investigate the potential role of MSC-induced tumor vascular maturation increased drug delivery observed vivo. Experimental Design: Mice bearing s.c. FaDu human head neck squamous cell carcinoma xenografts treated with MSC (0.2 mg/d × 14 days orally). Changes microvessel density...

10.1158/1078-0432.ccr-08-0212 article EN Clinical Cancer Research 2008-06-15

Background Successful angioplasty is one of the main factor limb salvage during critical ischemia. In complex femoropopliteal to infrapopliteal occlusions, an anterograde recanalization attempt can fail in up 20% cases. The purpose this dual center pilot study was evaluate acute success and clinical impact retrograde transpedal access for below‐the‐knee chronic total occlusions after failed late complications at puncture site. Methods angiographic data 51 consecutive patients with CLI...

10.1002/ccd.25262 article EN Catheterization and Cardiovascular Interventions 2013-10-19
Coming Soon ...